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The prevalence of obesity in the USA and worldwide has reached epidemic proportions during the last two decades. Drugs
currently available for the treatment of obesity provide no more than 5% placebo-adjusted weight loss and are associated with
undesirable side eﬀects. Peroxisome proliferator-activated receptor (PPAR) modulators oﬀer potential beneﬁts for the treatment
of obesity and its associated complications but their development has been complicated by biological, technical, and regulatory
challenges. Despite signiﬁcant challenges, PPAR modulators are attractive targets for the treatment of obesity and could oﬀer a
viable alternative to the millions of patients who fail to lose weight following rigorous dieting and exercise protocols. In addition,
PPAR modulators have the potential-added beneﬁt of ameliorating the associated comorbidities.
Copyright © 2008 Myl` ene Perreault et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
During the last two decades, the incidence of obesity has
tripled in developing countries, with more than 1.1 billion
adults overweight worldwide and 312 million of them obese
[1]. Obesity has been causally linked to the development of
certain forms of cancer, cardiovascular disease, sleep apnea,
psychiatric disorder, and type 2 diabetes (T2D) [2–6]. In
parallel to the growing rate of obesity, the incidence of
T2D has also dramatically increased worldwide, and it is
believed that more than 366 million people will become
diabetic by 2030 [1]. Recent ﬁndings point toward visceral
adiposity as a causal link for the development of obesity-
induced T2D. Visceral adipose tissue (VAT) is metabolically
more active than subcutaneous adipose tissue and secretes a
number of adipokines [7, 8]. The surgical removal of as little
as 0.6kg (0.8% total fat) of VAT signiﬁcantly ameliorated
insulin sensitivity in obese patients [9], whereas removal of
large amounts of subcutaneous adipose tissue did not [10].
These ﬁndings suggested that adipose tissue can no longer
be considered an inert tissue strictly involved in lipid storage
butis ratheranendocrine organcapableofregulating several
aspects of metabolism.
Currently, a few drugs are approved for the long-term
treatment of obesity but their eﬃcacy is limited. Both
sibutramine (Meridia) and orlistat (Xenical) have been
available for approximately 10 years for the treatment of
obesity but these agents only induce modest one-year weight
loss of 4.2% and 2.9%, respectively [11]. More recently, the
cannabinoid receptor-1(CB1) inverse agonist, rimonabant,
has been associated with signiﬁcant weight loss in several
global clinical trials, including RIO-Europe, RIO-Lipids,
RIO-Diabetes, and RIO-North America [11]. Although
rimonabant induced an approximately 5% placebo-adjusted
weight reduction in those studies, it was not approved in
the USA principally due to neurological and psychiatric
safetyconcerns[12].Recently,theantidiabeticGLP-1agonist
exenatide (Byetta) was shown to signiﬁcantly reduce mean
bodyweight(−4.7%)frombaselineafter2yearsoftreatment
[13]. This drug oﬀers beneﬁts over existing therapies as
it combines weight loss and improvements in glycosylated
hemoglobin (HbA1c), liver function, and blood pressure
[13]. Side eﬀects including nausea and vomiting have been
noted [14] and rare cases of acute pancreatitis have been
reported [15]. However, exenatide is currently not approved
for the treatment of obesity.
With no more than 5% placebo-adjusted weight loss
observed with currently available treatments, more drugs
are thus needed to provide patients with safe and eﬃca-
cious therapeutic options. Recent ﬁndings have suggested2 PPAR Research
that peroxisome proliferator-activated receptor (PPAR) delta
agonists could induce body weight loss by increasing energy
expenditure and fatty acid oxidation [16]. In fact, PPARδ
agonism either alone or in combination with agonism of
PPARα and/or PPARγ could not only induce body weight
loss but could also potentially improve other metabolic
parameters including insulin sensitivity and lipid proﬁles,
thus producing beneﬁts associated with the comorbidities of
the obese state.
2. MECHANISM OF ACTION OF PPARs
PPARs belong to the nuclear receptor family of transcription
factors and are master regulators of genes involved in
glucose and lipid metabolism. The PPARs are modular in
nature, containing an amino-terminal ligand-independent
AF1 transactivation domain, a DNA binding domain con-
taining two zinc ﬁnger motifs, and a carboxy-terminal
domain that contains a dimerization domain and a ligand-
dependentAF-2transactivationdomain[17].Therearethree
members of the PPAR family, PPARα,P P A R γ,a n dP P A R δ
[18]. They are 60–80% conserved in their DNA and ligand-
binding domains and are activated by a number of natural
and synthetic ligands, including eicosanoids, free fatty acids
(FFA), lipid lowering drugs (ﬁbrates), and the insulin
sensitizers (thiazolidinediones). PPARs heterodimerize with
the retinoic X receptor (RXR) and bindspeciﬁc promoter
sequences termed PPAR responsive elements (PPREs) in
their target genes. In the absence of a ligand, PPARs form
complexes with corepressors such as NcoR, RIP140, and
SMRT [19–21], which repress transcription through the
recruitment of histone deacetylases. Ligand binding induces
a conformational change that results in the dissociation of
corepressors and the recruitment of coactivators, such as
PPARγ coactivator-1(PGC-1),mediatorcomplex,P300/CBP
[22–24]. The speciﬁcity of complexes formed between the
receptor and corepressors or coactivators appears to be
determined by cell type, conformational change induced by
the ligand, and sequence of the DNA binding element. This
level of complexity allows ﬁne-tuning of the physiological
response and explains the variability of gene expression
changes when a receptor is activated by diﬀerent ligands.
2.1. PPARγ
PPARγ is the molecular target of thiazolidinediones (TZDs)
and has been well characterized in obese diabetic rodent
models and in diabetic patients. It is primarily expressed in
adipocytes, where it plays a pivotal role in the regulation
of adipocyte diﬀerentiation and lipid storage. Treatment of
diabetic animals or patients with TZDs increases subcuta-
neous fat mass area by inducing the number of small insulin
sensitive adipocytes in subcutaneous fat [25–28], while
decreasingvisceralfatmass[29,30].ThiseﬀectofTZDsmost
likely contributes to the improvement of insulin sensitivity,
although a direct eﬀect of PPARγ on skeletal muscle, liver,
and macrophages has also been demonstrated. For example,
it has been reported that the insulin sensitizing eﬀect of
rosiglitazone was attenuated in macrophage-speciﬁc PPARγ
knockout mice, suggesting that macrophages are important
for TZD-induced insulin sensitivity [31]. TZD treatment
has also been associated with signiﬁcant improvement of
skeletal muscle, liver, and adipose tissue insulin signaling in
both rodents and humans [30, 32, 33]. Additionally, PPARγ
agonists increase the expression of adiponectin, which
decreases hepatic glucose production through activation
of AMP-activated protein kinase (AMPK) [34]a n dc o u l d
thus contribute to TZD-induced improvement in insulin
sensitivity.
2.2. PPARα
PPARα is predominantly expressed in highly oxidative
tissues, including liver, skeletal muscle, brown adipose tissue,
andheart[35,36]andisthetargetoftheﬁbrateclassofdrugs
used for the treatment of dyslipidemia. Fibrates decrease
triglyceride levels in both rodents and humans by depleting
the pool of free fatty acids (FFAs) through peroxisomal and
mitochondrial fatty acid oxidation. PPARα activation has
been associated with increased expression of genes involved
in all steps of fatty acid utilization, including the breakdown
of triglyceride particles to free fatty acids by lipoprotein
lipase (LPL), the transport of free fatty acids inside the
cells by fatty acid transport proteins (FATPs), and the
peroxisomal and mitochondrial β-oxydation by activation
of acyl CoA oxydase (ACO) and medium chain acyl CoA
decarboxylase (MCAD). In addition, PPARα is involved in
the reverse cholesterol transport pathway and contributes
to HDL production in humans by increasing the expression
of the major constituent of high-density lipoprotein (HDL)
cholesterol, apolipoprotein A1 (ApoA1) [37], as well as
increasing theATP-binding cassettetransporterA1(ABCA1)
[37].
Recently, PPARα has also been implicated in the reg-
ulation of body weight through appetite suppression. In
rodents, PPARα agonists, including WY-14643, fenoﬁbrate,
and oleoylethanolamide (OEA), have been reported to
i n d u c eb o d yw e i g h tl o s si naP P A R α-speciﬁc manner
[38, 39]. One of the proposed mechanisms involves stim-
ulation of speciﬁc regions of the brain controlling satiety
through [40] vagal nerve activation. Interestingly, PPARα
agonists can no longer induce appetite suppression in rats
in which the vagal nerve has been severed [38]. It is also
possible that PPARα induces appetite suppression through
other mechanisms, including FGF-21 secretion [41–43]o r
increased fatty acid oxidation and production of ketone
bodies [44, 45].
2.3. PPARδ
PPARδ has recently been characterized in rodents and
humans and is more widely distributed than its two coun-
terparts with high level of expression in skeletal muscle,
heart, kidney, adipose tissue, liver, and macrophages [46].
The physiological role of PPARδ has been elucidated not
only through genetic approaches, but also by pharmaco-
logical activation of the receptor with speciﬁc agonists,
including GW501516. A major role for PPARδ in bodyMyl` ene Perreault et al. 3
weight regulation has been reported in mice overexpressing
a constitutively active form of PPARδ in adipose tissue.
These mice are resistant to diet-induced obesity (DIO)
and are protected against the development of genetically
inducedobesitythroughinductionofenergyexpenditurevia
mitochondrial fatty acid oxidation and energy uncoupling
[16]. It is also possible that PPARδ induces body weight loss
by centrally regulating appetite suppression since PPARδ was
shown to mediate the hyperphagic response following focal
cerebral ischemia [47].
In addition to inducing body weight loss, PPARδ acti-
vation has been shown to improve lipid proﬁle by depleting
the pool of fatty acids through mitochondrial fatty acid
oxidation [16, 48] and by increasing reverse cholesterol
transport [49]. Two-week treatment of healthy volunteers
with GW501516 signiﬁcantly increased HDLc and decreased
triglycerides as compared to placebo-treated subjects [50].
PPARδ expression is upregulated in skeletal muscle of T2D
subjects and high-fat fed rats after bouts of exercise [46, 51–
54] and may play a role in providing a continuous source of
energy to support the increasing energy demand. Consistent
with this hypothesis, skeletal muscle overexpression of
PPARδ wasassociatedwithsigniﬁcantmuscle-typeswitching
from glycolytic to oxidative ﬁbers, further supporting its
role in lipid oxidation [55]. Interestingly, skeletal muscle
PPARδ transgenic mice were more resistant to fatigue after
intense exercise [55], suggesting a PPARδ-induced switch in
substrate utilization that helped maintain a higher level of
energy demand.
In addition to inducing weight loss and improving lipid
proﬁles, PPARδ agonism has the potential to improve insulin
sensitivity and glucose metabolism [46, 56]. Recently, this
hasbeenshowntoincludeacrucialroleforPPARδ expressed
in tissue macrophages [57, 58]. Activation of resident
macrophages in metabolic tissues toward the inﬂammatory
(M1) phenotype appears to play a role in insulin resistance
as a result of obesity. However, through production of Th2
cytokines,bothadipocytesandhepatocytesareabletoinduce
PPARδ expression in resident macrophages leading to their
alternative activation toward the anti-inﬂammatory M2 phe-
notype. This then results in increased insulin sensitivity in
these tissues, and could underlie some of the improvements
in glucose metabolism seen in PPARδ-treated animals.
3. CHALLENGES TO THE DEVELOPMENT OF
PPARδ MODULATORS
Following the publication of several high-proﬁle studies
implicating PPARδ as a potential target for obesity and
associated metabolic disorders, multiple pharmaceutical
companies have initiated drug discovery eﬀorts to identify
speciﬁc PPARδ,P P A R α/δ,P P A R γ/δ, and pan PPAR modu-
lators. However, development of these PPAR agonists faces
signiﬁcant challenges including major diﬀerences in PPAR
biology between rodents and humans, diﬃculties in predict-
ing in vivo eﬃcacy from simple in vitro models of activity,
toxicological ﬁndings arising from weight reduction through
targeting β-oxidation of fatty acids, and safety requirements
unique to PPAR biology and drug development.
3.1. DifferencesinPPARpharmacologybetween
rodentsandhumans
Despite very high homology between human and rodent
PPAR receptors, major biological and physiological dif-
ferences exist between these species. One clear and well-
understood example relates to peroxisome proliferation and
liver enlargement with PPARα agonists. In rodents, but
not humans, PPARα activation leads to hepatic peroxisome
proliferation associated with liver enlargement and cell
necrosis. One potential biological explanation for these
diﬀerencesisthathepaticPPARαexpressionisapproximately
10 times higher in rodents versus humans [59].
Similarly, it has been reported that PPARδ pharmacology
diﬀers between higher species and rodents. Contradicting
reports suggest that pharmacological PPARδ activation
inconsistently regulates body weight [55, 60, 61]a n dc h o l e s -
t e r o lo rt r i g l y c e r i d el e v e l si nr o d e n t s[ 55, 60–62]. However,
signiﬁcant elevation of HDL cholesterol and/or reduction
of LDL cholesterol and triglyceride have been reported in
obese rhesus monkeys and humans after chronic PPARδ
agonist administration [50, 63]. One potential explanation
may reside in the observation that the rodent ApoA-1
promoter diﬀers from the human promoter by 3 nucleotides,
resulting in a nonfunctional PPRE site [64, 65]. Interestingly,
PPARδ agonistshavebeenshowntodecreasetriglycerideand
increase HDL cholesterol in humanized ApoA-1 transgenic
mice [66] suggesting that mice can positively respond to
PPARδ activation once provided with a functional ApoA1
gene. Overall, these species diﬀerences could make the
observation of PPARδ driven outcomes more diﬃcult in
rodents, and thus complicate the development of PPARδ
modulators.
3.2. Complexityinducedbyligand-speciﬁceffects
Traditionally, the potency and aﬃn i t yo fP P A Rm o d u l a t o r s
have been determined using multiple assays, including
displacement of radiolabeled compound, displacement and
recruitment of corepressors and coactivators, and cell-based
transcriptional activation assays. Often, the in vitro potency
in binding and transcriptional activation assays correlates
with in vivo eﬃcacy, a notable example is the hypoglycemic
eﬀects of TZDs. TZDs with more potent in vitro activities
are often more active in rodent models [67, 68]. In some
cases, these correlations do not hold, reﬂecting a more
complex relationship between simple in vitro measures and
in vivo pharmacology that is best understood in the context
of the selective PPAR modulator (SPPARM) hypothesis.
The SPPARM concept emerged to describe the complete
spectrum of PPAR conformation/activation states leading
to each speciﬁc biological response. This model stipulates
that PPAR modulators turn on and oﬀ speciﬁc genes by
recruiting or releasing a complex assortment of coactivators
and corepressors. The coactivators and corepressors are
likely tissue speciﬁc and diﬀerent modulators are believed
to recruit diﬀerent sets of proteins leading to various degree
of gene activation/repression. This level of complexity pro-
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associated with PPAR activation by selecting modulators
that are recruiting/releasing speciﬁc sets of coactivators and
corepressors. However, this complexity also complicates the
development of PPAR agonists because species diﬀerences
can exist concerning coactivator expression and recruitment,
tissue speciﬁcity and availability.
Consistent with the SPPARM hypothesis, Berger et al.
reported that PPARγ/δ agonists L-165461 and L-783483
had similar binding aﬃnities and transcriptional activities
against PPARγ and PPARδ while the glucose lowering eﬀect
was more pronounced with L-783483 in db/db mice [67].
We have observed that PPAR pan modulators with similar
proﬁles in transcriptional cell-based assays can yield signif-
icantly diﬀerent in vivo activities (Table 1) despite similar
pharmacokinetic properties. These diﬀerences likely stem
from diﬀerential interactions with the ligand-binding pocket
of each PPAR resulting in modulator-speciﬁc diﬀerential
recruitment of coactivators/corepressors.
3.3. Challengesassociatedwiththedevelopmentof
weight-reducingagentstargetingoxidationof
fattyacids
It is well understood that body weight is physiologically
regulated through two major mechanisms: food intake and
energy expenditure. Energy expenditure can be positively
or negatively modulated by regulating metabolic rate, body
temperature,or level of physical activity. Targeting metabolic
rate through oxidation of free fatty acids and/or energy
uncoupling are eﬀective ways to induce body weight loss. For
example, it has been shown that targeted deletion of acetyl-
CoA carboxylase-2 (ACC2), an enzyme responsible for the
synthesis of malonyl-CoA, is associated with approximately
10–20% body weight loss caused by signiﬁcant increase in
total energy expenditure, with no change [71] or increased
food consumption [72]. The increased energy expenditure
was mostly explained by a signiﬁcant increase in fatty acid
oxidationandnotanelevationofthelevelofphysicalactivity
[71, 72]. Similarly, transgenic mice with muscle-speciﬁc
activation of PPARα are resistant to diet-induced obesity
despite consuming similar amounts of food compared to
nontransgenic mice [73]. As expected, the rate of palmitate
oxidation and the level of expression of genes regulating
mitochondrial and peroxisomal β-oxidation were increased
in muscle-speciﬁc PPARα transgenic mice [73]. Overall,
these studies provided convincing evidence that speciﬁcally
targeting oxidation of fatty acids is a relevant mechanism to
induce body weight loss.
PPARδ is known to inﬂuence all of the parameters
regulating energy expenditure by increasing the transport
and oxidation of free fatty acids in adipose tissue and
skeletal muscle, increasing thermogenesis and energyuncou-
pling in adipose tissue and inducing muscle ﬁber-type
switching to promote endurance and resistance to fatigue.
Recently, PPARδ has been suggested as a potential target
for body weight loss because of its role in fatty acid
oxidation. In mouse and human skeletal muscle, PPARδ
activation increases the expression of several genes involved
in mitochondrial oxidation of free fatty acids, including
carnitine palmitoyltransferase-1 (CPT-1), medium chain
acyl-CoA dehydrogenase (MCAD), long chain acyl-CoA
dehydrogenase (LCAD), and PGC-1α [16, 48, 55, 74]a n d
its pharmacological activation has been associated with body
weight loss in rodents [48, 55].
Currently, controversies exist as to whether an increased
rate of fatty acid oxidation is beneﬁcial. Numerous studies
have been published demonstrating that an elevated rate of
β-oxidation is beneﬁcial because it depletes the pool of fatty
acids required to synthesize triglyceride particles, prevents
accumulation of fatty acid metabolites in skeletal muscle
and other nonfat tissues, and induces body weight loss.
However, it has been shown that sustained level of fatty acid
oxidation, through long-term ﬁbrate treatment or PPARα
overexpression, is associated with skeletal and heart muscle
degeneration [75], cardiomyopathy [76, 77], and insulin
resistance [73] in mice. Consistent with these reports, we
have previously observed that pan PPAR activation induced
signiﬁcant levels of skeletal muscle degeneration and liver
vacuolation and necrosis in mice, but these observations
were completely absent in PPARα knockout animals (M.
Perreault et al., unpublished observations). Collectively,
these results suggest that sustained levels of fatty acid
oxidation through PPARα and potentially PPARδ could
signiﬁcantly improve some metabolic parameters but with
potential deleterious eﬀects on muscle and liver.
It has been proposed that the detrimental eﬀects of
sustained fatty acid oxidation result from the production of
reactive oxygen species produced during peroxisomal and
mitochondrial oxidation of fatty acids. The ﬁrst and rate-
limiting step of peroxisomal β-oxidation, ACO, generates
hydrogen peroxide during oxidation of acyl-CoAs. It has
been reported that hydrogen peroxide levels are signiﬁcantly
increased in the heart of cardiac-speciﬁc PPARα transgenic
mice and this eﬀect is exacerbated on a high-fat diet,
where the substrates for fatty acid oxidation are more
abundant [76]. Similarly, oxidation of fatty acids through
mitochondrial β-oxidation has been associated with an
increased production of reactive oxygen species (ROSs) as
long-chain fatty acids provide reducing equivalents that fuel
the electron transport chain.
While the role of PPARα in skeletal and cardiac muscle
degeneration has been established in rodents, the eﬀect
of PPARδ activation on these parameters is less clear. It
has been reported that PPARδ activates distinct metabolic
programs in the mouse heart as compared to PPARα,
leading to cardioprotection in the setting of myocardial
ischemia/reperfusion injury [77]. The exact mechanism for
the cardioprotection is currently unknown, but in contrast
to PPARα,P P A R δ overexpression induced cardiac glucose
oxidation as opposed to fatty acid oxidation [77]. Normal
hearts exhibit substrate ﬂexibility by switching between
lipid and glucose to match the metabolic state. However,
diabetic hearts mostly rely on fatty acids, leading to exces-
sive rates of myocardial fatty acid oxidation concomitant
with reduced glucose oxidation. In the heart of cardiac-
speciﬁc PPARα transgenic mice, genes involved in fatty
acid uptake, lipogenesis, and triglyceride synthesis (fatty
acid transport protein (FATP), CD36, glycerol-3-phosphateMyl` ene Perreault et al. 5
Table 1: Compounds with similar in vitro proﬁles induced diﬀerent in vivo eﬃcacy.
Compound In vitro potentcy (μM) Weight loss Insulin (% reduction) Adiponectin (fold increase)
αγ δ
1 [69, 70] 6.0 0.1 5.0 Weight neutral 30% 2.1
2 [69, 70] 3.0 0.1 1.0 14% 80% 3.2
acyltransferase (GPAT), acyl-CoA synthetase (ACS), fatty
acidsynthase(FAS),microsomaltriglyceridetransferprotein
(MTP)) were signiﬁcantly elevated while genes involved
in glucose metabolism (glucose transporter 4 (GLUT4),
phosphofructokinase (PFK)) were not. In contrast, the
expression of fatty acid transport and esteriﬁcation genes
was unchanged in cardiac-speciﬁc PPARδ transgenic mice
while genes regulating glucose metabolism were signiﬁcantly
elevated. These results further contribute to the hypothesis
suggesting that increased and sustained rate of fatty acid
oxidation could be detrimental for cardiac functions and
suggestthatthismechanismisPPARα-speciﬁc.Furthermore,
it has been reported that PPARδ activation is associated with
elevated expression of catalase [78], an enzyme responsible
for hydrogen peroxide degradation potentially providing an
additional protective eﬀect.
Recently, the concept of incomplete fatty acid oxidation
has emerged as another potential explanation for fatty acid
oxidation-induced metabolic disturbances. It was proposed
that obesity results in an excessive fatty acid load on
mitochondria causing accumulation of incompletely oxi-
dized intermediates, including acylcarnitine esters, while
decreasing levels of metabolites of the tricarboxylic acid
(TCA) cycle [79]. The exact mechanism leading to metabolic
disturbances is still unknown and whether acylcarnitine
esters directly induce insulin resistance and metabolic disor-
ders remains to be determined.
3.4. Safetystudyrequirementsuniqueto
PPARbiologyanddrugdevelopment
PPARgamma(TZDs)andalpha(ﬁbrates)agonistshavebeen
used for many years to treat type 2 diabetic and dyslipidemic
patients, respectively. TZDs (Avandia and Actos) are very
w e l lc h a r a c t e r i z e di nr o d e n t sa n dh u m a n sa n dr e s u l ti n
signiﬁcant improvements in insulin sensitivity and glycemic
control but are associated with increases in body weight
and ﬂuid retention that can exacerbate congestive heart
failure. The liabilities associated with PPARγ agonists are
observed in a small but signiﬁcant number of patients
and are very closely related to their eﬃcacy, as reduction
in HbA1c is directly correlated to body weight gain [80].
PPARγ-associated weight gain and ﬂuid retention liabilities
are well understood and can be reversed by discontinuing
drug administration or by treating with diuretics.
Recently, the PPARγ activator rosiglitazone has been
suggested to directly aﬀect cardiac function independent
from its eﬀects on ﬂuid retention. A number of meta-
analyses concluded that rosiglitazone signiﬁcantly increased
the rates of myocardial infarction and death by cardio-
vascular causes [81, 82]. However, controversies exist as
several recent studies refuting those results have been
published [83, 84]. Interestingly, a signiﬁcant lower risk of
death, myocardial infarction and stroke was observed with
pioglitazone (Actos) [85], suggesting a diﬀerence between
rosiglitazone and pioglitazone in relation to cardiovascular
eﬀects. Pioglitazone has been previously shown to improve
lipid proﬁle (triglyceride, LDL and HDL cholesterol) by
weakly activating PPARα, while rosiglitazone seems to
worsen these parameters which could contribute to the
deleteriouseﬀectsoncardiacfunctions[86–88].Theﬁndings
from these meta-analyses will have to be conﬁrmed with
cardiovascular outcome studies, as the clinical trials included
in these analyses were not originally designed to evaluate
cardiovascular endpoints. The RECORD study is a clinical
trial evaluating the eﬀects of rosiglitazone in approximately
2000 patients to speciﬁcally address cardiovascular eﬀects
as primary outcomes. The interim analysis indicated no
signiﬁcant increased myocardial infarction and death with
rosiglitazone, however, the authors admitted that their
study might be underpowered due to lower cardiovascular
events in this patient population and that the analysis was
performed before completion of the study [89–92].
Whether the cardiovascular eﬀects of rosiglitazone and
pioglitazone are conﬁrmed or not with clinical outcome
studies, these recent ﬁndings have changed the way reg-
ulatory agencies review and approve drugs and protein
therapeutics for the treatment of T2D. Earlier this year, the
FDA published their draft guidance for the development of
new diabetes therapeutics. The guidance aﬃrms that in the
absence of cardiovascular signal, long-term cardiovascular
studies could be conducted postapproval in a reasonable
timeframe [93]. However, large outcome trials should be
conducted prior to submission of regulatory dossiers for
drugs that show nonclinical or clinical evidence of increasing
cardiovascular risk [93].
In addition to the cardiovascular eﬀects, multiple PPAR
modulators have been discontinued over the last several
years due to carcinogenicity ﬁndings in rodents. Because
of the prevalence of positive carcinogenicity ﬁndings with
PPAR agonists and the lack of complete understanding of
PPAR-induced tumor development, 2-year carcinogenicity
studiesinmiceandratsarenowrequiredbeforeclinicaltrials
longer than 6 months in duration can be initiated [93, 94].
Moreover, PPARγ activation has recently been linked to an
increased risk of fracture in humans [95–97]. It has been
proposed that PPARγ activators could have a direct eﬀect
on osteoblastogenesis [98, 99] and osteoclastogenesis [100]
in rodents, but further clinical studies will be necessary to
understand if these mechanisms are also involved in TZDs-
induced bone loss in humans. Despite an increased risk
of fracture with PPARγ activators in humans, the role of6 PPAR Research
other PPAR isoforms on bone formation and resorption
is less clear. The presence of PPARδ both at protein and
mRNA levels has been reported in rat bone tissue sections,
preosteoblasts, rodent and human osteoblastic cell lines as
well as rabbit osteoclasts [101–104], while PPARα has been
found in preosteoblasts, chondrocytes, and human periph-
eral blood mononuclear cell (PBMC)-derived osteoclasts
[101] .T h er o l eo fP P A R α and PPARδ in bone formation and
resorption needs to be further determined.
4. SUMMARY AND PERSPECTIVES
Obesity and associated disorders are serious diseases aﬀect-
ing millions of people worldwide. The therapeutic options
currently oﬀered are providing limited eﬃcacy and are
coupled with several serious side eﬀects. Despite signiﬁ-
cant challenges associated with their development, PPAR
modulators are potential new obesity therapies that could
oﬀer not only weight management opportunities but also
amelioration of the associated disorders by correcting the
causes of insulin resistance and dyslipidemia. Molecules
targeting PPARδ, alone or in combination with other
PPARs, oﬀer signiﬁcant advantages as PPARδ seems to have
beneﬁcial cardioprotective eﬀects in rodents by modulating
fuel utilization in addition to its anti-inﬂammatory and lipid
eﬀects. Whether or not such weight-modulating therapies
will be relevant to humans and ultimately approvable by
regulatory agencies remain to be determined.
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